The Reply - 17/09/17
Doi : 10.1016/j.amjmed.2017.05.033
Antonia Sophocleous, PhD a, b, Roy Robertson, MD c, d, Nuno B. Ferreira, PhD e, James McKenzie, RGN a, c, William D. Fraser, MD f, Stuart H. Ralston, MD a
a Rheumatology and Bone Diseases Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, UK
b Department of Life Sciences, School of Sciences, European University of Cyprus, Nicosia
c Muirhouse Medical Group, Edinburgh, UK
d Centre for Population Health Sciences, University of Edinburgh, UK
e Department of Clinical and Health Psychology, University of Edinburgh, UK
f Department of Medicine, University of East Anglia, Norwich, UK
Le texte complet de cet article est disponible en PDF.
| Funding: The study was supported by a program grant from Arthritis Research UK (17713). |
|
| Conflict of Interest: SHR is inventor on a patent concerning the use of cannabinoid receptor ligands as treatments for osteoporosis and other bone diseases. |
|
| Authorship: The first draft of the manuscript was prepared by SHR, biochemical analyses were supervised by WDF, statistical analysis was conducted by AS and NBF. All authors revised the manuscript for intellectual content. |
© 2017
Elsevier Inc. Tous droits réservés.
Vol 130 - N° 10
P. e457 - octobre 2017 Retour au numéro
Article précédent
- Is Determination of Predictors by Cross-Sectional Study Valid?
- Shiva Mansouri Hanis, Kamyar Mansori
- Prognostic Value of High-Sensitivity Cardiac Troponin T Compared with Risk Scores in Stable Cardiovascular Disease: Methodological Issues
- Saeid Safiri, Erfan Ayubi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?